Can-Fite Announces Late-Breaking Abstract Presentation on Namodenosona?? Phase II Results at the American Association of Clinical Oncology (ASCO) Annual Meeting

BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company
with a pipeline of proprietary small molecule drugs that address cancer,
liver and inflammatory diseases, announced today that a late-breaking
abstract detailing results from the Company's recently completed
multicenter Phase II trial in patients with advanced liver cancer has
been accepted for oral presentation at the late-breaking abstract
session of the 54th Annual Meeting of the American Society of
Clinical Oncology (ASCO). The worlda??s largest clinical cancer research
meeting, ASCO, will take place from May 31 to June 4, 2019 in Chicago,

The abstract titled: "A phase II, randomized, double-blind,
placebo-controlled trial evaluating efficacy and safety of namodenoson
(CF102), an a3 adenosine receptor agonist (A3AR), as a second-line
treatment in patients with Child-Pugh B (CPB) advanced hepatocellular
carcinoma (HCC)a??, will be presented in an oral session by Prof. Salomon
Stemmer, Principal Investigator of the Phase II trial.

Oral Abstract Presentation Details
Tuesday, June 02, 2019

Time: 8:00 am CDT
abstract session: Developmental Immunotherapy and Tumor Immunobiology

"We consider ASCOa??s acceptance of our late breaking oral presentation a
testament to the compelling data coming out of our recently completed
Phase II study of Namodenoson. We believe this reflects the oncology
communitya??s assessment that our Phase II Namodenoson trial is a
high-impact study with significant relevance in the treatment of liver
cancer,a?? stated Can-Fite CEO Pnina Fishman.
See also:
Leave a comment
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »